Enterprise Value

-14.76M

Cash

77.29M

Avg Qtr Burn

-17.05M

Short % of Float

6.09%

Insider Ownership

15.40%

Institutional Own.

55.95%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 3

Data readout

IMU-856 Details
Celiac disease

Phase 2b

Initiation

Vidofludimus calcium (IMU-838) Details
Multiple sclerosis, Autoimmune disease

Phase 2

Data readout

Vidofludimus calcium (IMU-838) Details
Primary sclerosing cholangitis, Bile duct disease, Liver disease

Failed

Discontinued

Failed

Discontinued

Vidofludimus calcium (IMU-838) Details
COVID-19, Infectious disease

Failed

Discontinued

Vidofludimus calcium (IMU-838) Details
Inflammatory bowel disease, Bowel disorder, Ulcerative colitis

Failed

Discontinued